Sai Life Sciences Q1FY26 Revenue Rises 77 Per Cent YoY

08 Aug 2025 CW Team

Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.

Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.

Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.

Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.

To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.

Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”

CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”

Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO), reported strong financial results for the first quarter of fiscal year 2026, led by significant growth in its CDMO segment.Revenue from operations in Q1FY26 stood at Rs 4.96 billion, a 77 per cent increase over the Rs 2.80 billion recorded in Q1FY25. The company reported EBITDA of Rs 1.25 billion, a 305 per cent year-on-year jump, while EBITDA margin expanded by 14 percentage points to 25 per cent. Profit after tax stood at Rs 600 million for the quarter.Sai Life Sciences invested Rs 1.34 billion in capital expenditure during the quarter, reflecting its commitment to infrastructure expansion and scientific innovation.Key business milestones included the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), adding 91 KL of capacity and bringing the total manufacturing capacity to approximately 700 KL. The company also inaugurated a new Peptide Research Centre at its Hyderabad R&D campus, as well as a 10,300 sq. ft. biology facility with multiple laboratories to bolster its integrated discovery platform.Construction is underway on a new Medicinal Chemistry block with capacity for 200 fume hoods and a new Process R&D Block at Unit 2, Hyderabad. This expansion is expected to nearly double the company’s PRD capacity and enhance its capabilities in early-phase peptide development and clinical formulations. Additionally, Sai Life is preparing to build an extra 200 KL production capacity at Bidar, set for completion by Q3FY27.To support this growth, the company onboarded 253 new scientists and technical staff in Q1FY26.Managing Director and CEO Mr Krishna Kanumuri stated, “We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. These investments reflect our proactive approach in supporting complex and emerging drug modalities.”CFO Mr Siva Chittor added, “Our robust Q1FY26 performance was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues. Margin expansion was driven by scale efficiencies, productivity gains, and operating leverage across sites.”Looking ahead, the company remains focused on scaling execution, deepening client partnerships, and investing in R&D capabilities to sustain long-term value creation.

Building Material

11 Dec 2025

Suraj Estate Wins Euromoney Award for India’s Best Residential Developer

"Suraj Estate Developers Limited has received the Euromoney Real Estate Award 2025 for ‘India’s Best Residential Developer’, positioning the company among globally benchmarked leaders in the sector. The recognition reflects its four-decade legacy in delivering high-quality residential and redevelopment-led projects across South Central Mumbai. The Euromoney Real Estate Awards, presented by the London-based Euromoney magazine, are widely regarded as one of the most credible global assessments of performance in real estate, banking and finance. Winners are selected through surveys of inte..

Building Material

11 Dec 2025

Lloyds Metals, Tata Steel Sign MoU to Explore Strategic Collaboration

"Lloyds Metals and Energy Limited has signed a non-binding Memorandum of Understanding with Tata Steel Limited to evaluate potential areas of strategic cooperation across mining, logistics, pelletisation and steelmaking. The MoU was signed by B Prabhakaran, Managing Director of Lloyds Metals, and Mr T V Narendran, CEO and Managing Director of Tata Steel. The partnership framework aims to leverage the natural operational synergies between both companies and assess opportunities in greenfield steel projects, iron ore mining, slurry pipeline infrastructure, pellet manufacturing in iron ore–ric..

Building Material

11 Dec 2025

IndiaAI, Gujarat Govt Host Regional Conclave Ahead of 2026 AI Summit

The IndiaAI Mission under the Ministry of Electronics and Information Technology, along with the Government of Gujarat and IIT Gandhinagar, convened a Regional Pre-Summit Event at Mahatma Mandir, Gandhinagar. The initiative is part of the build-up to the India–AI Impact Summit 2026, scheduled for 15–20 February 2026 at Bharat Mandapam, New Delhi. The conclave brought together senior policymakers, technology leaders, researchers and industry practitioners to examine how AI can accelerate economic, digital and social transformation across sectors. The programme focused on the overarching th..